Syneron's elure(TM) Advanced Dermal Whitening Product Line Wins the Prestigious International Technology Award in the New Technology Launch Category

YOKNEAM, Israel, April 16 /PRNewswire-FirstCall/ -- Syneron Medical Ltd. (Nasdaq: ELOS), an innovator in the development, marketing and sales of elos™ combined-energy medical aesthetic devices, won first place in Cosmetics & Toiletries (C&T) magazine's 5th International Technology Award presented at the In-Cosmetic show in Paris, France. This prestigious award recognized the launch of Syneron's elure™ Advanced Dermal Whitening product and its significance within the cosmetic R&D industry.

The elure™ Advanced Dermal Whitening product line is the first scientifically proven enzymatic skin whitening treatment that utilizes a unique scientific discovery of a naturally occurring bio-active substance called Melanozyme™. Melanozyme acts to immediately target and disintegrate the melanin to diminish dark colored pigment in the skin safely, with virtually no side effects. Unlike many other whitening products on the market, the elure product line does not contain Hydroquinone, which has been reported to cause side effects such as skin redness and burning sensations.  In addition, while other skin whitening products inhibit the formation of melanin, elure acts to target and disintegrate melanin resulting in a much faster whitening effect.  elure™ Advanced Dermal Whitening was introduced in November 2009 at the world renowned cosmetic show in Asia, Cosmoprof Hong Kong.  The "TRY IT ON THE SPOT" campaign captivated the audience as they observed first hand the dramatic effect of elure on melanin. Once elure was applied, the melanin decomposed "on the spot".

C&T magazine received a record breaking 57 entries in total for the 2010 awards. These entries were judged by a panel of twelve experts in cosmetics R&D to arrive at the six finalists.  Syneron's elure was nominated one of the three finalists, and then the winner of the New Technology Launch Category Award for 2010.  "We are very pleased with the recognition that RBT and Syneron got by this award," said Dr. Shimon Eckhouse, Chairman of Syneron Medical.  "The great work performed by the elure team resulted in this significant achievement, which is part of our long term strategy to offer the most advanced and effective technology to the global aesthetic market."

For more information about elure™ Advanced Dermal Whitening product line visit www.syneron.com or www.elureskin.com.

About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com and www.candelalaser.com.

SOURCE Syneron Medical Ltd.